In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Riding The Tailwind Of Healthtech Through The Pandemic And Beyond

COVID-19 Has Not Put The Brakes On Resurgence Of Health Care, Say Asia-Based VC Investors

Executive Summary

VC investors and medtech strategists alike at APACMed’s 2020 virtual conference agreed that the challenges presented by COVID-19 have given healthtech a higher profile and accelerated the arrival of health system workflow improvements.

You may also be interested in...



Mining The Deep Tech Seam Of Innovation For Healthtech Gold

Singapore-based SGInnovate has a unique multi stakeholder business model focused on identifying and funding Deep Tech start-ups. CEO Jui Lim now plans to increase the group’s activity in advanced manufacturing and “wetware”  ̶   drugs and diagnostics – as firms increasingly are able to revert to pre-COVID business plans.

VC View: Riding The Waves Of Asia’s Healthtech Explosion

Asia continues to gain attention for its healthtech innovation and adoption activity, and VC investors have seen the merits of a maintaining a focus on this newly emerging regional innovation hotspot, regardless of the pandemic.

The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’

The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV124614

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel